Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.

Circulation · 2018 · PMC5839936 · PMID 28974520

Europe PMC DOI

hedged sentences

0.0000

closest p · 0.0× alpha

0.0560

boldest claim

The sentences

highly significantP =2e−16actually significant

Cross-treatment comparison of the within-participant changes revealed a highly significant reduction in absolute Framingham risk favoring torcetrapib plus atorvastatin over atorvastatin alone (−1.5%; P =2e−16).

also in 132,142 other papers

borderline significantP =0.056so close (0.05 < p ≤ 0.1)

5 Limitations The atorvastatin-only treatment arm had a slight, borderline significant reduction in the 9-protein risk score at 3 months from baseline (0.43% absolute risk reduction, P =0.056), when perhaps no effect would have been expected.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.